
Dr. Donna Culton discusses the elevated mortality risk in patients with bullous pemphigoid at EADV 2025
This chapter highlights other histologic features beyond eosinophil count that may be present in patients with EoE.
Professor Mona Bafadhel presents a comprehensive overview of type 2 inflammation in COPD, exploring its underlying mechanisms, clinical manifestations, and implications for patient outcomes.
This chapter highlights how a food bolus impaction may be the initial manifestation of a patient with EoE masked by adaptive eating behavior.

Join Dr. Werth as she outlines how early diagnosis and treatment are critical to minimize risk and improve long term outcomes in patients with BP.
In this ADVENT symposium at the 2024 EADV meeting, Dr. Donna Culton focuses on the challenges of diagnosis and the unmet needs for patients with BP.
Learn how to identify chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation using blood eosinophil (EOS) levels, understand the associated risks, and recognize factors that may influence EOS counts.

Dr. Stella Lee and Profs. Peter Hellings and Wytske Fokkens discuss type 2 inflammation, partnering with patients to improve outcomes, and real-world data on biologic effectiveness in CRSwNP.
Unpack the keys to successful disease control in CRSwNP alongside expert Prof. Vibeke Backer. Learn how to navigate treatment pathways for improved patient quality of life.

Navigate through this interactive infographic to learn more about why lung function is important to monitor in pediatric patients with asthma and the noninvasive procedures that are available for implementation in clinical practice.

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr. Marta Ferrer discusses how chronic spontaneous urticaria profoundly impacts mental health and quality of life, with patients often undergoing extensive testing before receiving appropriate treatment.
Join pediatric respirologist Dr. Sharon Dell and adult respirologist Dr. Simon Couillard as they discuss the prognostic and diagnostic power of asthma biomarkers and their impact on optimizing patient management across all ages.